Breaking News, Collaborations & Alliances

Agilent Completes BIOVECTRA Acquisition

Expands its portfolio of CDMO services, adds rapidly growing modalities and brings world-class capabilities to support gene editing.

Author Image

By: Charlie Sternberg

Associate Editor

Agilent Technologies Inc. has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.   All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group.   “We are delighted to officially welcome the BIOVECTRA team to Agilent,” s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters